quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:43:44·15d
ANALYSTRating
Pharvaris N.V. logo

Wolfe Research initiated coverage on Pharvaris N.V. with a new price target

PHVS· Pharvaris N.V.
Health Care
Original source

Companies

  • PHVS
    Pharvaris N.V.
    Health Care

Recent analyst ratings

  • Apr 9UpdateWolfe Research$42.00
  • Mar 9UpdateRBC Capital Mkts$52.00
  • Oct 15UpdateH.C. Wainwright$60.00
  • Oct 9UpdateBofA Securities$27.00
  • Jun 11UpdateGuggenheim$32.00
  • Apr 29UpdateCantor Fitzgerald$28.00

Related

  • INSIDER14m
    Chief Early Development Lesage Anne exercised 7,600 shares at a strike of $7.62 and sold $441,726 worth of shares (14,700 units at $30.05) as part of a pre-agreed trading plan (SEC Form 4)
  • INSIDER1h
    Chief Medical Officer Lu Peng exercised 7,101 shares at a strike of $2.59 and sold $213,405 worth of shares (7,101 units at $30.05) as part of a pre-agreed trading plan (SEC Form 4)
  • SEC1d
    SEC Form 144 filed by Pharvaris N.V.
  • SEC1d
    SEC Form 144 filed by Pharvaris N.V.
  • INSIDER3d
    SEC Form 4 filed by Lu Peng
  • INSIDER3d
    SEC Form 4 filed by Modig Berndt
  • PR4d
    Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
  • SEC7d
    SEC Form 144 filed by Pharvaris N.V.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022